Last reviewed · How we verify
Other COPD medication
At a glance
| Generic name | Other COPD medication |
|---|---|
| Sponsor | AstraZeneca |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Study to Investigate Airway Inflammation With Dupilumab Subcutaneously in Participants Aged ≥40 to ≤85 Years With Chronic Obstructive Pulmonary Disease. (PHASE4)
- Venous Congestion And Cognitive Dysfunction After Cardiac Surgery
- Pilot Study of Performance Status 2 vs. Performance Status 0-1 Non-small Cell Lung Cancer Patients Treated With Chemo/Immunotherapy (PHASE2)
- Montelukast in Parkinson Disease (PHASE2, PHASE3)
- Expand Pulmonary Rehabilitation to Other Chronic Respiratory Diseases Than COPD (NA)
- Impact of Multi-Component Interventions on High-Risk COPD Smokers (NA)
- Sarcopenia Magnetic Resonance Imaging Evaluation (SUSIE)
- Comparative Effects of Triple Inhaled Therapy With Budesonide/Glycopyrronium/Formoterol Versus Fluticasone Furoate/Umeclidinium/Vilanterol on Small Airway Disease in COPD Patients: A Randomized Crossover Study (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Other COPD medication CI brief — competitive landscape report
- Other COPD medication updates RSS · CI watch RSS
- AstraZeneca portfolio CI